Bovine Respiratory Syncytial Virus (BRSV)

Bovine Respiratory Syncytial Virus (BRSV) is one of the most important viral causes of respiratory disease in cattle worldwide. This highly contagious virus causes respiratory illness ranging from mild upper respiratory infection to severe, life-threatening pneumonia, with young calves being particularly susceptible to serious disease. BRSV represents a major component of the bovine respiratory disease complex and contributes significantly to economic losses in both dairy and beef operations through morbidity, mortality, treatment costs, and reduced performance.

BRSV infection occurs in cattle populations globally, with the virus considered endemic in most cattle-raising regions. Seroprevalence studies indicate that the majority of cattle have been exposed to BRSV by adulthood, though clinical disease typically occurs in young animals or during primary outbreaks in naive populations. The virus spreads rapidly through susceptible groups, particularly under conditions of stress or crowding, making it a significant concern in calf-rearing facilities, feedlots, and situations involving cattle movement and commingling.

The economic and welfare impact of BRSV stems from both direct losses due to illness and death and the virus's role in predisposing cattle to secondary bacterial pneumonia. Outbreaks in calf-rearing facilities can cause devastating losses, with mortality rates sometimes exceeding twenty percent in severely affected groups. Even in cases where mortality is limited, the cost of treatment, reduced growth rates, and lasting effects on lung health create substantial economic burden. The welfare implications of respiratory distress and illness in affected animals add important concerns beyond pure economics.

Understanding BRSV biology and epidemiology enables development of effective prevention and control programs. While no specific antiviral treatment exists, supportive care and management of secondary infections can significantly improve outcomes. Vaccination programs, though imperfect, provide meaningful protection and should be incorporated into comprehensive respiratory disease prevention strategies. Recognition of risk factors and implementation of appropriate management practices help reduce BRSV incidence and severity in cattle operations.

The primary cause of BRSV infection is the bovine respiratory syncytial virus, a member of the Pneumoviridae family closely related to human respiratory syncytial virus (RSV). The virus is an enveloped, negative-sense RNA virus that primarily infects epithelial cells of the respiratory tract. The name derives from the characteristic syncytia (fused multinucleated cells) formed during viral replication in infected tissues. BRSV is relatively fragile in the environment, being readily inactivated by heat, drying, and common disinfectants, which limits its survival outside the host.

Transmission of BRSV occurs primarily through respiratory secretions via aerosol droplets and direct nose-to-nose contact between infected and susceptible cattle. The virus can spread rapidly through groups of cattle in close contact, with transmission facilitated by coughing and sneezing that generate infectious aerosols. Indirect transmission through contaminated equipment, clothing, or personnel is possible but less important than direct animal-to-animal spread. The incubation period following exposure ranges from three to seven days, after which viral shedding begins and can continue for one to two weeks.

Environmental and management factors significantly influence BRSV transmission dynamics and disease severity. Crowding and close confinement accelerate viral spread through susceptible populations. Poor ventilation in housed cattle concentrates infectious aerosols and increases exposure dose. Seasonal patterns are evident in many regions, with peak incidence typically occurring during fall and winter months when cattle are more likely to be housed indoors. Stress factors including transportation, weaning, weather extremes, and nutritional deficiencies impair immune function and increase susceptibility to severe disease.

Risk factors for BRSV include both animal characteristics and management situations. Young calves between one and six months of age face the highest risk of severe disease, though animals of all ages are susceptible. Calves with declining maternal antibody levels are particularly vulnerable, as passive protection wanes without acquired immunity developing. Cattle recently introduced to new environments, such as feedlot arrivals or purchased animals, face elevated risk. Concurrent infection with other respiratory pathogens, particularly bovine viral diarrhea virus (BVDV), increases susceptibility and disease severity.

The pathophysiology of BRSV involves viral replication in respiratory epithelium followed by inflammatory responses that can cause significant tissue damage. The virus initially infects cells of the upper respiratory tract, then spreads to the lower airways and lung tissue. Viral replication damages ciliated epithelial cells, impairing mucociliary clearance and predisposing to secondary bacterial infection. The immune response to infection, particularly the inflammatory component, contributes substantially to clinical disease, with severe cases showing extensive pneumonia and emphysema. An immunopathologic component is recognized, where excessive or dysregulated immune responses actually worsen disease, which has implications for both vaccine development and treatment approaches.

Early warning signs of BRSV infection are often nonspecific and can be easily overlooked in their initial stages. Affected cattle may show slightly reduced appetite, with less enthusiastic approach to feeding. Mild depression characterized by decreased alertness or subtle drooping of the head may be apparent to careful observers. Low-grade fever may be present before respiratory signs become obvious. Occasional coughing or mild nasal discharge may be noted. These early signs may be present for one to three days before more characteristic respiratory symptoms develop.

Common symptoms of established BRSV infection center on respiratory tract involvement with accompanying systemic illness. Fever typically ranges from 104°F to 107°F (40°C to 41.7°C) during acute infection. Nasal discharge progresses from serous (clear and watery) to mucopurulent as disease advances and secondary bacterial infection develops. Coughing becomes frequent, often harsh and paroxysmal in character. Increased respiratory rate and effort are readily apparent, with affected cattle breathing noticeably faster and harder than healthy animals. Depression deepens, with affected cattle appearing dull and uninterested in their surroundings.

Behavioral changes in cattle with BRSV reflect respiratory compromise and systemic illness. Affected animals often stand with head extended and neck stretched forward to ease breathing. They may be reluctant to lie down, standing for extended periods as recumbency increases respiratory difficulty. Feed intake decreases substantially, with severely affected animals stopping eating entirely. Cattle may separate from the group, seeking isolated areas of the pen or pasture. Activity levels decrease markedly, with affected animals reluctant to move even when encouraged.

Physical examination findings reveal the extent of respiratory involvement in BRSV cases. Auscultation of the lungs typically reveals abnormal sounds including increased bronchial tones, crackles, wheezes, and areas of absent or diminished breath sounds over consolidated lung regions. Subcutaneous emphysema, air trapped under the skin particularly over the back and withers, may develop in severe cases, creating a characteristic crackling sensation on palpation. Mouth breathing and excessive salivation indicate severe respiratory compromise. Conjunctivitis with watery eyes frequently accompanies respiratory signs.

Symptom progression in BRSV can be rapid, particularly in young calves and severe outbreaks. Initial mild signs typically progress over two to four days to peak clinical disease. In uncomplicated cases, improvement may begin within a week as the immune response controls viral replication. However, severe cases can deteriorate rapidly, sometimes progressing from apparent health to severe respiratory distress within twenty-four to forty-eight hours. Secondary bacterial pneumonia extends and complicates illness, with recovery taking two to three weeks or longer when bacterial infection is significant.

Emergency symptoms requiring immediate intervention include severe respiratory distress characterized by open-mouth breathing, extended head and neck, and audible respiratory noise. Frothy discharge from nose and mouth indicates pulmonary edema, a grave sign. Subcutaneous emphysema spreading beyond the thoracic region suggests air leakage from damaged lungs into tissues. Cyanosis, a bluish discoloration of mucous membranes, indicates severe oxygen deprivation. Collapse or inability to rise reflects advanced disease requiring urgent attention. Young calves showing rapid deterioration demand immediate intervention, as death can occur within hours in severe cases.

Clinical examination provides the foundation for BRSV diagnosis in field situations, though clinical signs alone cannot definitively distinguish BRSV from other causes of respiratory disease. The combination of fever, respiratory signs, coughing, and nasal discharge in groups of cattle, particularly young calves, raises suspicion of viral respiratory infection. Auscultation findings of widespread lung involvement, particularly emphysema and the pattern of rapid spread through susceptible groups, support BRSV diagnosis. However, confirmation requires laboratory testing, as multiple viral and bacterial pathogens produce similar clinical presentations.

Diagnostic testing for BRSV utilizes several approaches depending on the situation and available resources. Nasal swabs or deep nasopharyngeal samples can be submitted for virus detection through PCR testing, which offers high sensitivity and specificity. Viral isolation in cell culture provides definitive diagnosis but is slower and more technically demanding. Rapid antigen detection tests are available for point-of-care testing, though sensitivity may be lower than PCR methods. Serology, measuring antibody levels in paired acute and convalescent serum samples, can confirm recent infection but results come too late to guide immediate treatment decisions.

Differential diagnosis must consider other causes of respiratory disease in cattle that may present similarly to BRSV. Other viral agents in the respiratory disease complex including infectious bovine rhinotracheitis (IBR), bovine viral diarrhea (BVD), and parainfluenza-3 (PI3) cause overlapping clinical signs. Bacterial pneumonia from Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni may occur primarily or secondarily to viral infection. Mycoplasma bovis infection should be considered, particularly in chronic cases or those with joint involvement. Non-infectious causes of respiratory distress including aspiration pneumonia and acute bovine pulmonary edema and emphysema require differentiation.

Herd-level diagnostics become important in outbreak situations and for developing appropriate prevention strategies. Necropsy examination of fatal cases provides valuable diagnostic information, with characteristic lung lesions and tissue samples enabling pathogen identification. Lung tissue testing through PCR, culture, and histopathology helps characterize the pathogens involved. Review of vaccination histories, environmental conditions, and management factors helps identify risk factors contributing to the outbreak. Testing for concurrent infections, particularly BVDV, is important as persistent infection with BVDV predisposes cattle to severe BRSV and other respiratory diseases.

Emergency treatment for severe BRSV cases focuses on respiratory support and managing the inflammatory response contributing to clinical signs. Cattle in severe respiratory distress should be handled minimally and carefully, as stress can trigger acute deterioration in compromised animals. Oxygen supplementation benefits severely affected cattle when available. Corticosteroids such as dexamethasone may provide rapid anti-inflammatory effects in acute severe cases, though their use must be carefully considered due to potential immunosuppressive effects. Epinephrine may be indicated if acute allergic-type reactions to inflammation are suspected. Emergency cases require intensive monitoring and may need repeated treatments over short intervals.

Medical management of BRSV recognizes that no specific antiviral treatment exists; therapy is therefore supportive and aimed at controlling secondary complications. Non-steroidal anti-inflammatory drugs (NSAIDs) such as flunixin meglumine, meloxicam, or ketoprofen reduce inflammation, control fever, and improve animal comfort. These medications may help modulate the immunopathologic component of disease that contributes to severe clinical signs. Antibiotic therapy is routinely administered to control or prevent secondary bacterial pneumonia, which significantly impacts outcomes in many BRSV cases. Selection of antibiotics follows principles similar to treatment of bacterial respiratory disease, considering spectrum, penetration into lung tissue, and withdrawal times.

Supportive care plays a crucial role in BRSV case outcomes and should be optimized for affected cattle. Ensuring easy access to fresh, clean water encourages hydration in febrile cattle. Providing palatable, high-quality feed supports energy needs and helps maintain rumen function. Environmental management should minimize respiratory challenge and stress—affected cattle benefit from good ventilation without drafts, protection from weather extremes, and reduced dust exposure. Rest is important, with affected animals benefiting from minimal handling and reduced stress. Separating sick animals enables closer observation and reduces transmission to healthy cattle.

The immunopathologic component of BRSV has implications for treatment approach. Excessive or dysregulated immune responses contribute to disease severity in some cases, suggesting that judicious anti-inflammatory therapy may benefit outcome beyond simple symptom control. However, suppressing immune responses too aggressively could impair viral clearance and predispose to secondary infection. The balance between controlling harmful inflammation while preserving protective immunity presents a clinical challenge. Veterinary guidance helps optimize this balance based on individual case factors.

Herd treatment protocols should establish approaches for consistent management of BRSV cases within operations. Protocols should define criteria for identifying affected animals and initiating treatment. Standard treatment regimens should specify anti-inflammatory and antibiotic selections, doses, and duration. Criteria for evaluating treatment response and modifying therapy should be established. Protocols should address drug withdrawal requirements and record-keeping needs. Regular review of treatment outcomes enables protocol refinement.

Treatment decisions must consider realistic outcome expectations and economic factors. Early, appropriate treatment of BRSV cases generally yields good outcomes in uncomplicated cases. Severe cases with extensive lung damage face more guarded prognosis, and some animals succumb despite aggressive treatment. Chronic cases with permanent lung damage may never return to full productivity. Treatment costs, potential performance losses in survivors, and the animal's value influence decisions about treatment intensity and duration. For animals not responding to treatment or developing severe complications, humane euthanasia may be appropriate.

Recovery timeline for BRSV varies substantially based on disease severity, development of secondary complications, and promptness of treatment. Mild cases with limited lung involvement may show marked improvement within several days and return to near-normal function within one to two weeks. Moderate cases typically require two to three weeks for clinical recovery, though some lung damage may persist. Severe cases with extensive pneumonia may require four to six weeks or longer for resolution, and permanent lung damage is common in these animals. Fatal cases typically occur within the first week of severe illness.

Post-treatment care and monitoring should continue beyond resolution of acute symptoms. Recovered cattle should be observed for signs of relapse or development of secondary complications. Activity levels and appetite should be monitored as indicators of ongoing recovery. Respiratory rate and effort during normal activity and light exertion provides information about residual lung function. Cattle that recovered from severe BRSV may show exercise intolerance or respiratory distress with exertion due to permanent lung damage. Some animals develop chronic respiratory problems requiring ongoing management.

Prognosis factors influencing recovery outcomes include age at infection, severity of initial disease, timing of treatment, and development of complications. Young calves under two months of age have higher mortality rates than older animals. Cases identified and treated early in the disease course have better outcomes than those treated after extensive lung damage develops. Secondary bacterial pneumonia significantly worsens prognosis and extends recovery time. Concurrent infections, particularly BVDV, negatively impact outcomes. Animals with severe emphysema or extensive lung consolidation face guarded to poor prognosis for return to full productivity.

Return to production considerations recognize that BRSV survivors may have lasting effects on performance. Cattle with significant lung damage often exhibit reduced growth rates compared to unaffected contemporaries. Feed efficiency may be permanently impaired in animals with chronic lung compromise. In dairy operations, heifers experiencing severe respiratory disease as calves may have reduced milk production potential. These performance effects should be considered in management and marketing decisions. Drug withdrawal periods must be observed before slaughter of treated animals.

Vaccination represents a primary tool for BRSV prevention, though vaccines provide incomplete protection due to the immunopathologic nature of disease and challenges in developing optimal respiratory tract immunity. Both modified live virus (MLV) and killed virus vaccines are available, with MLV vaccines generally providing stronger cellular immune responses important for viral control. Intranasal MLV vaccines stimulate local respiratory immunity at the site of viral entry. Vaccination timing should ensure protection before anticipated exposure periods, with young calves particularly benefiting from early vaccination. Booster doses according to manufacturer recommendations enhance protection.

Biosecurity measures help limit BRSV introduction and spread within cattle populations. Purchasing cattle from known sources with documented health histories reduces disease introduction risk. Quarantine of new arrivals, when practical, allows identification of incubating respiratory disease before exposure of resident cattle. Separation of age groups, particularly maintaining young calves apart from older cattle that may be virus reservoirs, reduces transmission to the most vulnerable animals. Good sanitation of facilities and equipment between animal groups reduces environmental contamination.

Nutritional prevention supports immune competence essential for controlling BRSV infection. Ensuring adequate colostrum intake provides calves with maternal antibodies conferring early protection. Maintaining appropriate energy and protein nutrition throughout the calf's development supports immune system maturation. Trace minerals including copper, zinc, and selenium are essential for optimal immune function. Vitamin A and vitamin E support respiratory epithelium health and immune responses. Avoiding nutritional stress during high-risk periods enhances disease resistance.

Management practices influence BRSV transmission and disease severity and should be optimized to reduce risk. Adequate ventilation in housed cattle reduces infectious aerosol concentration and lowers respiratory challenge. Avoiding overcrowding reduces direct contact transmission opportunities. Minimizing stress through gentle handling, gradual management changes, and maintaining consistent routines supports immune function. Controlling other respiratory pathogens through comprehensive vaccination programs reduces mixed infections that worsen BRSV outcomes. Climate control to avoid extremes of temperature and humidity reduces respiratory stress.

Quarantine and testing protocols help protect against disease introduction. New arrivals should ideally be separated from resident cattle for two to three weeks, allowing observation for respiratory disease development. Testing of incoming cattle for BVDV persistent infection removes a major risk factor for severe respiratory disease. During outbreaks, affected groups should be isolated from healthy cattle to limit spread. Movement restrictions during active outbreaks prevent transmission to other parts of the operation. Following resolution, facilities should be cleaned and rested before introducing new susceptible animals.

Daily management and monitoring for respiratory health requires systematic observation of cattle for early disease signs. All cattle should be observed at least twice daily, with particular attention to groups at high risk for BRSV including young calves and recently stressed animals. Observers should watch for subtle early signs including mild depression, reduced feed intake, and slight increase in respiratory rate or effort. Coughing should be noted, distinguishing single occasional coughs from frequent or productive coughing suggesting disease. Consistent, trained observation enables early identification and treatment, improving outcomes.

Environmental and facility management significantly impacts BRSV risk and should be optimized for respiratory health. Ventilation systems in enclosed housing must provide adequate air exchange without creating drafts directly on animals. Air quality should be monitored subjectively through odor and dust levels and managed through appropriate bedding, cleaning schedules, and ventilation adjustments. Temperature extremes stress cattle and impair respiratory defenses, warranting climate control where possible. Crowding increases disease transmission and should be avoided, with stocking densities maintained at or below recommended levels.

Herd health programs addressing BRSV should be integrated with comprehensive respiratory disease prevention. Vaccination programs should include BRSV components administered according to appropriate schedules for the operation type and risk level. Calf health programs should emphasize colostrum management, appropriate nutrition, and vaccination timing to protect during the vulnerable post-colostral period. Receiving protocols for purchased cattle should include vaccination, quarantine, and careful monitoring. Regular veterinary consultation ensures programs reflect current best practices.

Record keeping and monitoring systems enable evaluation of respiratory disease control program effectiveness. Individual animal records should document respiratory disease events, treatments, and outcomes. Group or pen-level tracking of respiratory morbidity and mortality provides herd perspective. Vaccination records should confirm appropriate timing and coverage of the population. Review of these records over time identifies trends requiring attention and documents program improvements. Necropsy records from fatal respiratory cases help characterize pathogens involved and guide prevention efforts.

Economic considerations influence BRSV management decisions at all levels. Prevention programs including vaccination, facilities improvements, and management changes require investment but typically provide positive returns through reduced disease losses. Treatment costs for individual cases must be weighed against animal value and recovery likelihood. The long-term performance impacts of severe respiratory disease affect lifetime value of affected animals. Comprehensive cost-benefit analysis helps optimize resource allocation for respiratory disease control.

All cattle breeds are susceptible to BRSV infection, with no breed demonstrating complete resistance. Research has not identified substantial breed differences in susceptibility to BRSV specifically, though general differences in immune function between breeds may influence disease severity. Bos indicus breeds and their crosses may show somewhat better overall respiratory disease resistance compared to British and European Bos taurus breeds, though this has been more extensively studied for bacterial respiratory disease than for BRSV specifically. Individual variation in disease susceptibility exists within all breeds.

Production type and management system strongly influence BRSV exposure risk and disease impact. Dairy calves raised in intensive housing systems face substantial BRSV challenge due to close confinement and frequent exposure to respiratory pathogens. Beef calves on extensive range operations may have lower exposure but can experience severe outbreaks when naive groups encounter the virus. Feedlot cattle face high risk during the receiving period when stressed cattle from multiple sources are commingled. Within any production system, young calves represent the highest-risk group for severe disease and mortality.

Genetic selection and testing for BRSV resistance is not currently practiced, as specific genetic markers for resistance have not been identified for practical application. General selection for health traits and reduced respiratory disease susceptibility may provide some indirect benefit. Research into the genetics of immune response to respiratory pathogens continues and may eventually enable selection for improved resistance. Currently, management factors including vaccination, colostrum management, environmental control, and stress reduction provide the primary tools for reducing BRSV impact across all breeds.

Commonly co-occurring conditions with BRSV primarily include other components of the bovine respiratory disease complex. Bacterial secondary infection with Mannheimia haemolytica, Pasteurella multocida, or Histophilus somni frequently complicates BRSV infection, contributing significantly to morbidity and mortality. Other respiratory viruses including infectious bovine rhinotracheitis (IBR), bovine viral diarrhea (BVD), and parainfluenza-3 (PI3) may occur concurrently, particularly during respiratory disease outbreaks in susceptible populations. Mycoplasma bovis infection may accompany or follow BRSV, sometimes causing chronic pneumonia and associated joint infections.

Conditions with similar symptoms to BRSV require differentiation for appropriate management. Other viral respiratory infections produce overlapping clinical signs and can only be definitively distinguished through laboratory testing. Bacterial pneumonia may present similarly, particularly when occurring as a primary infection rather than secondary to viral disease. Acute bovine pulmonary edema and emphysema, typically triggered by pasture changes or toxin exposure, causes sudden severe respiratory distress. Foreign body pneumonia from aspiration presents with respiratory signs but different epidemiology. Allergic respiratory conditions, though less common, can produce acute respiratory compromise.

Complications and sequelae of BRSV extend beyond the acute illness period and significantly impact long-term animal health and productivity. Secondary bacterial pneumonia develops in many BRSV cases and extends illness duration, worsens prognosis, and increases treatment requirements. Pulmonary emphysema with bullae formation can lead to rupture and pneumothorax or subcutaneous emphysema. Chronic bronchopneumonia may persist following acute illness, causing ongoing respiratory compromise and reduced performance. Permanent lung damage, including fibrosis and bronchiectasis, results in lifelong exercise intolerance and predisposition to future respiratory problems in severely affected survivors.